Is there any impact of new drugs on the outcome of advanced NSCLC? An overview of the Southern Italy Cooperative Oncology Group Trials

Giuseppe Frasci, Nicola Panza, Giuseppe Comella, Giovanni Pacilio

Research output: Contribution to journalArticle

Abstract

Lung cancer represents the major cause of cancer-related death in Europe and North America, accounting for 28% of all cancer deaths. Seventy to 80% of all lung cancers are non-small cell lung cancers (NSCLCs), and approximately 75% of these patients present with locally advanced or disseminated disease. Even though chemotherapy is now recommended in the majority of cases of unresectable NSCLC, it still fails to substantially modify the fate of these patients. In recent years, several active cytotoxic drugs (paclitaxel, docetaxel, vinorelbine, gemcitabine, and irinotecan) have been developed, showing an overall response rate (ORR)

Original languageEnglish
Pages (from-to)379-385
Number of pages7
JournalThe oncologist
Volume4
Issue number5
Publication statusPublished - 1999

Keywords

  • Chemotherapy trials
  • Cisplatin
  • Gemcitabine
  • NSCLC
  • Survival
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Fingerprint Dive into the research topics of 'Is there any impact of new drugs on the outcome of advanced NSCLC? An overview of the Southern Italy Cooperative Oncology Group Trials'. Together they form a unique fingerprint.

  • Cite this